US5214030A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Calcitonin gene-related peptides for treating erectile dysfunctions
Assignee: Individual
•
Filing: 1990-04-21
•
Granted: 1993-05-25
•
Expires: 2010-04-21
Abstract
Abstract A method of treating erectile dysfunctions in mammals and men, by administering to the mammal or man a pharmaceutical composition comprising a therapeutically effective amount of a calcitonin gene-related peptide.
Inventors
- 👤 Georg Stief
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 22:53
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/225; A61K38/04; A61K38/07; A61P; A61P13/00; A61P13/02; A61P15/00; A61P43/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
232 words
A method of treating erectile dysfunctions in mammals, which comprises: administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of an active agent selected from the group consisting of (a) a calcitonin gene-related peptide having the general formula: ##STR3## wherein R 1 is either a hydrogen atom or a radical of the general formula R 2 --T-- wherein T is Ala or Ser and R 2 is a hydrogen atom or an acyl radical containing up to 4 carbon atoms; X and Y are, independently, methylene radicals or sulphur atoms; Q is Asp or Asn; A is Asp, Asn, Glu or Gly; B is Phe or Leu; D is Met or Val; E is Gly or Val; G is Asn, Ser or Asp; Ki is Lys or Glu; L is selected from the group consisting of Ala, Phe, Pro, Glu, Ser, Ile, Leu, Val, Tyr, Hypro, Gln, Hse, Thr, Asp, and Asn; M is selected from the group consisting of Phe, Pro, Hypro, Tyr, Ala, Val, Leu, Ile, Ser, Thr, Asp, Asn, Glu, and Gln; and R 3 is a hydroxyl group, an amino group, or a peptide of the sequence -Gly-Arg-Arg-Arg-Arg-Asp-Leu-Gln-Ala, -Gly-Arg-Arg-Arg-Arg, or -Gly-Lys-Lys-Arg; (b) a peptide having the formula of (a) in which up to 10 amino acids of the C-terminal end of the peptide are omitted; acceptable salts of the peptides defined in (a) or (b).
Claim 2
Independent Claim
232 words
A method of treating erectile dysfunctions in mammals, which comprises: administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of an active agent selected from the group consisting of (a) a calcitonin gene-related peptide having the general formula: ##STR3## wherein R 1 is either a hydrogen atom or a radical of the general formula R 2 --T-- wherein T is Ala or Ser and R 2 is a hydrogen atom or an acyl radical containing up to 4 carbon atoms; X and Y are, independently, methylene radicals or sulphur atoms; Q is Asp or Asn; A is Asp, Asn, Glu or Gly; B is Phe or Leu; D is Met or Val; E is Gly or Val; G is Asn, Ser or Asp; Ki is Lys or Glu; L is selected from the group consisting of Ala, Phe, Pro, Glu, Ser, Ile, Leu, Val, Tyr, Hypro, Gln, Hse, Thr, Asp, and Asn; M is selected from the group consisting of Phe, Pro, Hypro, Tyr, Ala, Val, Leu, Ile, Ser, Thr, Asp, Asn, Glu, and Gln; and R 3 is a hydroxyl group, an amino group, or a peptide of the sequence -Gly-Arg-Arg-Arg-Arg-Asp-Leu-Gln-Ala, -Gly-Arg-Arg-Arg-Arg, or -Gly-Lys-Lys-Arg; (b) a peptide having the formula of (a) in which up to 10 amino acids of the C-terminal end of the peptide are omitted; acceptable salts of the peptides defined in (a) or (b).
Claim 3
Dependent Claim
24 words
The method of claim 1, wherein L is selected from the group consisting of Ala, Val, Leu, Ile, Thr, Asp, Asn, Glu, and Gln.
Claim 4
Dependent Claim
21 words
The method of claim 1, wherein said calcitonin gene-related peptide is present in an amount of 0.5 μg to 5 mg.
Claim 5
Dependent Claim
36 words
The method of claim 1, wherein said pharmaceutical composition further comprises an active material selected from the group consisting of adenosine, vitamins, protaglandins, calcium antagonists, α-receptor blockers and relaxants of the smooth musculature, and mixtures thereof.
Claim 6
Independent Claim
33 words
A method of treating erectile dysfunctions in mammals, which comprises: administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of a human calcitonin gene-related peptide having the general formula: ##STR4##
Claim 7
Independent Claim
33 words
A method of treating erectile dysfunctions in mammals, which comprises: administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of a human calcitonin gene-related peptide having the general formula: ##STR4##
Claim 8
Dependent Claim
21 words
The method of claim 5, wherein said calcitonin gene-related peptide is present in an amount of 0.5 μg to 5 mg.
Claim 9
Dependent Claim
36 words
The method of claim 5, wherein said pharmaceutical composition further comprises an active material selected from the group consisting of adenosine, vitamins, prostaglandins, calcium antagonists, α-receptor blockers and relaxants of the smooth musculature, and mixtures thereof.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-24 | 1996-11-23 | 1997-05-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-24 | 2000-11-23 | 2001-05-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-24 | 2004-11-23 | 2005-05-25 | $7700.00 | Window Closed / Lapsed |